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Abstract
Background: The pathogenesis of Francisella tularensis, the causative agent of tularemia, has been primarily characterized in
mice. However, the high degree of sensitivity of mice to bacterial challenge, especially with the human virulent strains of F.
tularensis, limits this animal model for screening of defined attenuated vaccine candidates for protection studies.
Methods and Findings: We analyzed the susceptibility of the Fischer 344 rat to pulmonary (intratracheal) challenge with
three different subspecies (subsp) of F. tularensis that reflect different levels of virulence in humans, and characterized the
bacterial replication profile in rat bone marrow-derived macrophages (BMDM). In contrast to the mouse, Fischer 344 rats
exhibit a broader range of sensitivity to pulmonary challenge with the human virulent subsp. tularensis and holarctica.
Unlike mice, Fischer rats exhibited a high degree of resistance to pulmonary challenge with LVS (an attenuated derivative of
subsp. holarctica) and subsp. novicida. Within BMDM, subsp. tularensis and LVS showed minimal replication, subsp. novicida
showed marginal replication, and subsp. holartica replicated robustly. The limited intramacrophage replication of subsp.
tularensis and novicida strains was correlated with the induction of nitric oxide production. Importantly, Fischer 344 rats that
survived pulmonary infection with subsp. novicida were markedly protected against subsequent pulmonary challenge with
subsp. tularensis, suggesting that subsp. novicida may be a useful platform for the development of vaccines against subsp.
tularensis.
Conclusions: The Fischer 344 rat exhibits similar sensitivity to F. tularensis strains as that reported for humans, and thus the
Fischer 344 ray may serve as a better animal model for tularemia vaccine development.
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Introduction
Francisella tularensis is a gram negative bacterium that is the
causative agent of the human disease tularemia [1,2]. There is
currently no licensed vaccine for human use, but extensive efforts
are underway to identify potential vaccine candidates for this
biothreat agent. Most of our current understanding of pathogen-
esis and host immune responses comes from studies using the
mouse model of F. tularensis infection [3,4,5,6,7]. While the murine
tularemia model has extended our understanding of the disease
process, the extreme sensitivity of the mouse to F. tularensis
challenge limits the usefulness of this model in protection studies.
F. tularensis subsp. tularensis and holartica are virulent in humans
[1,8] and mice (LD50 ,10 CFU for subsp. tularensis and holartica in
mice via the pulmonary route) [9,10]. In contrast, F. tularensis
subsp. novicida and LVS, an attenuated vaccine strain derived from
subsp. holarctica, are avirulent in humans, [1,10] but highly virulent
in mice (LD50 ,10 CFU for subsp. novicida and LD50 ,10
4 CFU
for LVS in mice via the pulmonary route) [11,12,13]. Various
vaccination studies, using either LVS [6,9,14] or a variety of
defined F. tularensis vaccine strains [10,12,15], have been able to
show some level of protective efficacy in mice, but only against
very low challenge doses (10–500 CFU of subsp. tularensis)
[10,16,17]. Thus, it would be highly beneficial to identify an
alternative animal model that exhibits similar sensitivities to
Francisella infection as humans and provides a more reflective
platform for assessing vaccine candidates, with a wider window of
titratable protection.
One such alternative animal model for F. tularensis infections is
the rat. Historical studies suggested that ‘‘white rats’’ were much
less susceptible to F. tularensis challenges than mice [18,19]. It also
was found that several rat strains, including the Fischer 344 rat,
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initial studies, the rat model was overlooked in favor of the mouse
model, due in part to the availability of reagents and knockout/
transgenic strains to aid in understanding the mechanisms of host
immunity. Two recent studies have stimulated renewed interest in
the rat model of Francisella infection. Conlan and colleagues [23]
compared the relative susceptibilities of Fischer 344 and Sprague-
Dawley rats to intraperitoneal (IP) F. tularensis subsp. tularensis and
holarctica challenges, and suggested that the decreased sensitivity of
the Sprague-Dawley rats to these strains may provide a model to
assess host innate immune defenses. Also, Wu et. al [24] have
reported on the efficacy of subcutaneous or intradermal LVS
vaccination in Fischer 344 rats, which affords protection against a
broader range of subsp. tularensis pulmonary challenges.
In the current study, we sought to further extend these
observations with a comprehensive analysis of pulmonary
challenge of Fischer 344 rats with three different subsps. of F.
tularensis that exhibit varying degrees of virulence in humans. We
further characterized the bacterial replication profile of these
strains within rat macrophages. Our studies suggest that the
response of the Fischer 344 rat to the various F. tularensis strains
may be more reflective of how humans respond to these
organisms. These studies provide additional insight into the utility
of the rat model for screening potential vaccine candidates against
F. tularensis.
Results
In vivo susceptibility of Fischer 344 rats to pulmonary
challenge with Francisella strains
Recent publications have characterized the susceptibility of
Fischer 344 rats to LVS and F. tularensis subsp. tularensis pulmonary
challenge [24] and to IP infections with F. tularensis subsp. holarctica
(both wildtype and LVS strains) and F. tularensis subsp. tularensis
[23]. However, there has yet to be a full comparison of Fischer 344
rats infected with the four most widely studied strains via the same
route of inoculation. Since the pulmonary route of infection is the
most relevant for human vaccine development, we performed
experiments to determine the LD50 of four F. tularensis strains, F.
tularensis subsp. tularensis SCHU S4, F. tularensis subsp. holarctica
OR960246, F. tularensis subsp. holarctica LVS and F. tularensis subsp.
novicida U112, via pulmonary challenge of Fischer 344 rats.
Groups (n=6) of rats were inoculated by intratracheal
instillation with increasing doses (10
2 to 10
7 CFU) of subsp.
novicida, LVS, subsp. holarctica and subsp. tularensis and monitored
daily for survival. As shown in Table 1, rats were highly resistant to
subsp. novicida challenge, with an approximate LD50 of
5610
6 CFU. As recently reported by Wu et. al. [24], rats were
extremely resistant to LVS challenge. In fact, the rats in our study
did not exhibit any overt signs of illness with doses of LVS as high
as 10
7 CFU. In contrast, rats were more sensitive to subsp.
holarctica challenge (approx. LD50 of 1610
5 CFU). Rats showed
the highest sensitivity to pulmonary infection with subsp. tularensis
(approx. LD50 of 5610
2 CFU). Humans also show the greatest
susceptibility to subsp. tularensis infection, followed by susceptibility
to subsp. holarctica infection. Humans also are highly resistant to
LVS infections (since this was developed as a potential human
vaccine), as well as to subsp. novicida infections. While some rats did
succumb to pulmonary challenge with this subsp., it was only with
very high doses. The early time to death observed in those rats
which did succumb, along with the increased stimulatory
properties of subsp. novicida LPS over that of other subsp. [25],
suggests that death may have been caused by toxicity from the
large number of organisms rather than by a productive infection.
Overall, this data suggests that F. tularensis infections of the Fischer
344 rat may be a more representative model of human pulmonary
tularemia than the widely used mouse model.
Generation of bone marrow derived rat macrophages
and analysis of phagocytic ability
Because F. tularensis can survive and replicate within macro-
phages, a key attribute to its virulence, mouse bone marrow
derived macrophages (BMDM) have been used extensively as an in
vitro model to study F. tularensis infections. In order to further
characterize the Fischer 344 rat model, we determined how the
various F. tularensis strains replicated in rat BMDM. We first
compared the basal phagocytic capability of BMDM generated
from Fisher 344 rats to that of BMDM derived from BALB/c mice
to ensure that the macrophages generated from the rat were
functionally similar to those from mice.
To compare gross phagocytic ability, macrophages were seeded
in 6 well tissue culture plates (1610
6 cells/well) and incubated for
two hr with fluorescently labeled microbeads at a concentration of
either 10 or 100 beads per cell. Extracellular beads were then
washed off and the cells were labeled with either CD11b-
AlexaFluor 647 (Fisher 344 BMDM) or CD11b-APC (BALB/c
BMDM) to confirm the macrophage population. Cells were then
analyzed for the presence of intracellular beads by flow cytometry.
In a histogram plot (Fig. 1), the presence of one bead per cell is
indicated by the first positive peak (gate P5), and increasing
numbers of beads (2 beads and $3 beads) are evidenced by
successive peaks of increasing fluorescence intensity (gates P6 and
P7, respectively). As shown in Figure 1, at an initial concentration
of 10 beads per cell, approximately 29% of rat and 15% of mouse
BMDM contained beads, with the majority of cells containing only
one bead. When the concentration of beads was increased to 100
beads per cell, a greater percentage of both cell types (87% of rat
and 49% of mouse BMDM) contained beads, with the greatest
number of cells having taken up 3 or more beads. These results
indicated that BMDM generated from Fischer 344 rats have a
basal phagocytic ability better than those from BALB/c mice.
Uptake and replication of F. tularensis strains within
Fischer 344 bone marrow derived macrophages
Once we determined that BMDM from Fischer 344 rats readily
phagocytosed inert beads, we analyzed the ability of these cells to
phagocytose F. tularensis strains. Rat BMDM were seeded into 96
well plates (2610
5 cells/well), allowed to adhere, and then infected
(10 and 100 MOI) with subsp. novicida, LVS, subsp. holarctica and
Table 1. Intratracheal LD50 Doses of Francisella Strains in
Fischer 344 Rats.
Bacterial Strain
Intratracheal LD50
Dose (Approximate) MTD
subsp. novicida 5610
6 CFU 3 days
LVS .1610
7 CFU &30 days
subsp. holarctica 1610
5 CFU 10 days
subsp. tularensis 5610
2 CFU 10 days
Groups of Fischer 344 rats (n=6) were challenged intratracheally with
increasing doses (10
2 to 10
7 CFU) of subsp. novicida strain U112, subsp.
holarctica strain LVS, subsp. holarctica strain OR96-0246, or subsp. tularensis
strain SCHU S4 and monitored daily for morbidity and mortality and the LD50
and mean time to death (MTD) calculated. Results for each strain are
representative of at least two separate experiments.
doi:10.1371/journal.pone.0009952.t001
Francisella in the F344 Rat
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Immediately following this infection period, supernatants were
removed, cells were lysed with 0.2% deoxycholate, and serial
dilutions of both lysates and supernatants were plated to determine
CFU. As shown in Figure 2A, there were differences in bacterial
numbers of the various strains in the cell lysates, which represent
intracellular bacteria. The Fischer 344 BMDM were able to
phagocytose all of the four tested strains, but phagocytosis of
subsp. novicida was notably higher (1–2 log10) than phagocytosis of
LVS, subsp. holarctica and subsp. tularensis.
Since rat BMDM were capable of phagocytosing all of the F.
tularensis strains, we also analyzed the replication kinetics of these
strains within the cells. Rat BMDM were seeded in 96 well plates,
allowed to adhere, and infected with subsp. novicida, LVS, subsp.
holarctica and subsp. tularensis for two hr, as above. Cells were then
washed, treated for one hr with gentamicin to kill extracellular
bacteria, and then incubated for up to 72 hr. At the indicated time
points (3, 24, 48, 72 h) after infection, supernatants were removed,
cells were lysed and serial dilutions of lysates were plated to
determine CFU, which represent intracellular bacteria. As seen in
Figure 2B(i), 2 to 4 log10 of subsp. novicida were present
intracellularly at 3 hr after infection with 10 and 100 MOI, as
seen previously. By 24 h, the bacteria had replicated minimally
(approximately 1.5 log10), after which the intracellular bacterial
counts were reduced slightly, out to 72 hr. As shown in
Figure 2B(ii), very few (,2 log10) LVS were present intracellularly
at 3 h after infection, and intracellular bacteria remained at or
below the level of detection throughout the 72 hr time course. In
contrast, subsp. holarctica (Figure 2B(iii)) increased from low
intracellular numbers (1–3 log10) at 3 h after infection throughout
the entire time period, with an overall replication of 3 to 4 log10 by
72 hr after infection. Subsp. tularensis (Figure 2B(iv)) was found
intracellularly in similar numbers to subsp. holarctica at 3 hr, but
failed to replicate over the time course of the experiment, with few
intracellular bacteria found between 24 and 72 hr.
It has been previously shown that the addition of homologous
serum facilitates greater uptake of F. tularensis into human
monocytes [26,27]. Since LVS and subsp. tularensis exhibited the
lowest initial uptake into rat BMDM, we investigated whether the
addition of homologous rat serum would increase the initial
uptake, as well as the intracellular replication of the organisms.
Prior to inoculation into the BMDM, the LVS and subsp. tularensis
strains were first added to media which included 10% (v/v) naı ¨ve
Fischer 344 rat serum and placed in a shaking incubator (37uC,
220 RPM) for 30 minutes to promote opsonization. Bacteria
(10 MOI) were then added to the rat BMDM for 2 hr, gentamicin
treated, and intracellular numbers analyzed as above. As seen in
Figure 3, the addition of homologous serum did not increase
uptake or the replication of either LVS (3A) or subsp. tularensis
(3B).
Nitric oxide production by bone marrow derived
macrophages infected with F. tularensis strains
In order to investigate the possible basis for differences in
intracellular replication between the F. tularensis strains, we
analyzed the culture supernatants from intramacrophage replica-
Figure 1. Comparison of basal phagocytic ability of BMDM from Fischer 344 rats and BALB/c mice. Bone marrow derived macrophages
from (A) Fischer 344 rats and (B) BALB/c mice were seeded in 6 well plates (1610
6 cells/well) and allowed to adhere. Cells were incubated with
fluorescent microspheres (10 or 100 beads/cell) for 1 hr to allow for phagocytosis. Cells were collected into 5 ml polystyrene tubes and stained with
either mouse anti-rat CD11b AF647 or rat anti-mouse CD11b APC to confirm the macrophage population. The numbers of intracelllular beads were
quantified by flow cytometry (P5=1 bead, P6=2 beads, P7$3 beads). Results are representative of two separate experiments.
doi:10.1371/journal.pone.0009952.g001
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nitric oxide and TNFa, which are known to be produced by
macrophages after infection [28]. Induction of nitric oxide in
infected mouse macrophages has previously been shown to control
F. tularensis replication [4,29,30,31], thus we investigated whether
nitric oxide was produced by Fischer 344 BMDM upon infection
with F. tularensis using a spectrophotometric assay with Greiss
reagent. As shown in Figure 4A, nitric oxide was not detectable at
3 hr after infection of BMDM with any strain. Macrophages
infected with subsp. holarctica (4A(iii)) did not induce significant
levels of nitric oxide, which correlates with the high degree of
intracellular replication exhibited by this strain. In contrast,
macrophages infected with subsp. tularensis (4A(iv)) and LVS (4A(ii))
expressed relatively high levels of nitric oxide and these strains
exhibited minimal replication in these cells. Thus, the comparative
levels of nitric oxide produced by the infected macrophages
correlated with intracellular replication of the individual F.
tularensis strains. However, macrophages infected with subsp.
novicida (4A(i)) induced the greatest production of nitric oxide, with
up to 50 mM present at 48 hr after challenge, despite the ability of
subsp. novicida to replicate in these cells. Still, subsp. novicida only
replicated minimally in the macrophages, suggesting that nitric
oxide may contribute to limiting intracellular replication of this
strain as well. Levels of TNFa in culture supernatants of infected
macrophages were also measured and it was found that only
macrophages infected with subsp. novicida exhibited significant
levels of this cytokine (data not shown), demonstrating a lack of
correlation of rat BMDM TNFa production and the ability of the
individual F. tularensis strains to replicate intracellularly.
Inhibition of nitric oxide production leads to increased
intracellular F. tularensis replication
Since the F. tularensis strains that either replicated minimally or
failed to replicate within rat BMDM (subsp. tularensis, LVS and
subsp. novicida) also induced high levels of nitric oxide within the
BMDM, we determined the effect that inhibition of nitric oxide
production by the macrophages would have on F. tularensis
replication. BMDM were seeded as above and infected with
Figure 2. Uptake and replication of Francisella strains within
Fischer 344 rat BMDM. Bone marrow derived macrophages from
Fischer 344 rats were seeded in 96 well plates (2610
5 cells/well) and
allowed to adhere. Cells were infected (10 or 100 MOI) for two hr with
subsp. novicida, LVS, subsp. holarctica, or subsp. tularensis. (A) Serial
dilutions of culture supernatants (extracellular bacteria) and cell lysates
(intracellular bacteria) at (i) 10 MOI and (ii) 100 MOI were plated to
determine ability of macrophages to take up bacteria. Results are
representative of two separate experiments. (B) Following a 2 hr
infection period, cells were treated with gentamicin for 1 hr, and then
incubated at 37uC for 72 hr. At the indicated time points (3, 24, 48 and
72 h), cells were lysed and serial dilutions of lysates were plated to
quantify intracellular bacteria. Intracellular replication profiles of (i)
subsp. novicida, (ii) LVS, (iii) subsp. holarctica, or (iv) subsp. tularensis.
Results are representative of at least three separate experiments.
doi:10.1371/journal.pone.0009952.g002
Figure 3. Effect of naı ¨ve rat serum on uptake and replication of
Francisella strains within Fischer 344 rat BMDM. Bone marrow
derived macrophages were seeded in 96 well plates (2610
5 cells/well)
and allowed to adhere. Cells were infected (10 MOI) with (A) LVS or (B)
subsp. tularensis for 2 hr with or without 10% naı ¨ve rat serum as an
opsonin, treated for 1 hr with gentamicin, and incubated at 37uC for
72 hr. At the indicated time points (3, 24, 48, or 72 h) cells were lysed
and serial dilutions of lysates were plated to quantify intracellular
bacteria. Results are representative of two separate experiments.
doi:10.1371/journal.pone.0009952.g003
Figure 4. Contribution of Fischer 344 rat BMDM nitric oxide
production on intracellular replication of Francisella strains. (A)
Supernatants from intracellular replication assays (3, 24, 48 and 72 h)
were analyzed for the presence of nitric oxide. Concentrations of nitric
oxide following infection of BMDM with (i) subsp. novicida, (ii) LVS, (iii)
subsp. holarctica, and (iv) subsp. tularensis. Results are representative of
three separate experiments. (B) Fischer 344 BMDM were seeded in 96
well plates (2610
5 cells/well) and allowed to adhere. Cells were infected
with 10 MOI of (i) subsp. novicida or (ii) subsp. tularensis for 2 hr, with or
without N-methyl-L-arginine acetate salt as a nitric oxide inhibitor,
treated for 1 hr with gentamicin, and incubated at 37uC for 72 hr. At the
indicated time points (3, 24, 48 and 72 h) after challenge, cells were
lysed and serial dilutions were plated to quantify intracellular bacteria.
Results are representative of two separate experiments. *P,0.001,
**P,0.05.
doi:10.1371/journal.pone.0009952.g004
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induced the greatest levels of nitric oxide, and nitric oxide
inhibitor (1 mM concentration of N-methyl-L-arginine acetate
salt), was added to infected macrophages. As shown in figure 4B,
addition of nitric oxide inhibitor to the macrophages led to an
increase in intracellular replication of 2–3 logs for both subsp.
novicida (4B(i)) and subsp. tularensis (4B(ii)) when compared to
infected macrophages without inhibitor added. This demonstrates
that nitric oxide production by the Fischer 344 macrophages is
involved in limiting bacterial replication of these two F. tularensis
strains.
Ability of F. tularensis strains to replicate within Fischer
344 rat hepatocytes
The failure of subsp. tularensis to replicate within rat BMDM,
despite its high virulence within the rat, suggests that there might
be other cell types that are more permissive for intracellular subsp.
tularensis replication. It has been reported that following pulmonary
challenge with subsp. tularensis, the bacteria are disseminated to the
livers of Fischer 344 rats [24]. Since F. tularensis is able to replicate
in vitro within mouse hepatocytes [31], we decided to examine F.
tularensis replication within rat hepatocytes. Primary hepatocytes
isolated from the livers of Fischer 344 rats were infected with
10 MOI of subsp. novicida, LVS, subsp. holarctica and subsp.
tularensis, and intracellular replication for each strain was
determined. As shown in Figure 5A, subsp. novicida exhibited a
similar replicative profile within primary hepatocytes (an intial
replication of 1–2 log10 at 24 hr after which intracellular numbers
remained steady through 72 hr) as that seen with BMDM
(Fig. 2B(i)), except that much fewer bacteria were found
intracellularly at 3 hr in hepatocytes than in BMDM. Both LVS
(Fig. 5B), that was unable to replicate significantly, and subsp.
holarctica (Fig. 5C) that had relatively few bacteria intracellularly at
3 hr post infection but showed continual replication throughout
the 72 hr time period (3–4 log10 overall replication), exhibited
similar replication kinetics to what was seen in BMDM (Fig. 2B(ii)
and Fig. 2B(iii) respectively). Subsp. tularensis was also found at
relatively low levels intracelullarly at 3 hr post infection (Fig. 5D),
however, in contrast to BMDM (Fig. 2B(iv)), subsp. tularensis
demonstrated significant (P,0.01) intracellular replication in rat
hepatocytes throughout the 72 hr time course (3–4 logs replica-
tion). Thus, while subsp. novicida exhibited decreased intracellular
numbers in hepatocytes, the human virulent subsp. holarctica was
equally able to replicate in both cell types and the most virulent
subsp. tularensis strain, which was unable to replicate within rat
BMDM, was competent for replication within rat hepatocytes,
suggesting that cell types other than macrophages may be
important for replication of this pathogen in the rat.
Ability of subsp. novicida to induce a protective immune
response against subsp. tularensis in the Fischer 344 rat
Our data indicate that the sensitivity of the Fischer 344 rat to the
different F. tularensis strains is more similar to human sensitivity to
these strains, than is that of the mouse. Thus, F. tularensis infections
in the Fischer 344 rat may be more representative of human
pulmonary tularemia than the mouse model. In particular, the high
level of resistance of the rat (LD50 ,10
6 CFU) to pulmonary subsp.
novicida challenges compared to the exquisite sensitivity of the mouse
to this same challenge (LD50 ,10 CFU) is striking, considering that
subsp. novicida has extremely low virulence for humans (avirulent for
immunocompetent individuals). Given the (1) high degree of
resistance of the rats to pulmonary subsp. novicida challenge, (2)
the genetic similarity (98.1% homology between sequences
common to U112 and SCHU S4 [7,32]) with subsp. tularensis and
(3) similar growth characteristics in human macrophages [33], we
determined whether animals exposed to subsp. novicida would be
protected against subsequent challenge with the type A strain. Rats
challengedintratracheally(IT) withsubsp.novicida wererestedfor30
days and subsequently challenged IT with subsp. tularensis
(10
4 CFU). As shown in Fig. 6A, rats i.t. challenged with subsp.
novicida (10
2 and 10
5 CFU respectively) were greatly protected
(P=0.182 and P,0.05, respectively) following a lethal pulmonary
subsp. tularensis challenge (75% and 87% survival, respectively). In
contrast, the majority of rats not exposed to subsp. novicida (mock
vaccinated) but challenged with the same dose of subsp. tularensis,
succumbed to this infection (17% survival). These data demonstrate
protective efficacy of a live subsp. novicida vaccination in rats against
subsequent subsp. tularensis challenge via the pulmonary route.
We analyzed the cellular and humoral immune profiles induced
in rats by IT subsp. novicida inoculation. Rats challenged IT
(10
5 CFU) with subsp. novicida induced significant (P,0.001)
amounts of antigen-specific IFN-c production (4.26 ng/ml) in
isolated cervical lymph node cells compared to the same cells
isolated from mock-challenged animals (Fig. 6B), or rat cervical
lymph node cells cultured with the unrelated antigen hen egg
lysozyme (HEL). Serum antibody profiles were determined 30
days following IT subsp. novicida challenge. Strikingly, rats exposed
to subsp. novicida via the intratracheal route (10
5 CFU) showed
robust total antibody production (84065.78624337) and exhibited
a polarized (Th1) IgG2a response (40281.7623519) (Fig. 6C).
These results collectively demonstrate for the first time, using the
rat model, that IT vaccination with live subsp. novicida induces a
potent cellular and humoral response and confers significant
protection to subsequent pulmonary challenge with subsp.
tularensis.
Discussion
Macrophages are important host cells for intracellular F.
tularensis replication [4,7,27]. In mouse BMDM, the type A, type
B, LVS and subsp. novicida strains replicate to 3–4 log10 within
Figure 5. Intracellular replication of Francisella strains within
Fischer 344 hepatocytes. Livers were collected from Fischer 344 rats
and hepatocytes were isolated. Cells were seeded in 96 well plates
(2610
5 cells/well) and allowed to adhere. Cells were infected with
10 MOI of (A) subsp. novicida, (B) LVS, (C) subsp. holarctica or (D) subsp.
tularensis for 2 hr, gentamicin treated for 1 hr, and incubated at 37uC
for 72 hr. At the indicated time points after infection (3, 24, 48 and
72 hr), cells were lysed and serial dilutions were plated to quantify
intracellular bacteria. Results are representative of three separate
experiments. *P=0.02, **P,0.01.
doi:10.1371/journal.pone.0009952.g005
Francisella in the F344 Rat
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considered avirulent in humans, the bacterium was found to
replicate 3–4 log10 by 72 h of culture in human peripheral blood
monocytes and monocyte derived macrophages (hMDM) [33].
LVS and subsp. tularensis also have been shown to replicate in
hMDMs, however opsonization with autologous serum is required
for efficient uptake and replication of these two strains [26,27,35].
In the rat, we found that LVS was unable to replicate in Fischer
344 BMDM, and that while subsp. novicida was phagocytosed to a
greater extent initially, replication was limited to 1–2 log10 by
24 h. Subsp. tularensis and holarctica were taken up in relatively low
numbers initially, followed by minimal replication with subsp.
tularensis, but continued replication (2–3 log10) with subsp. holarctica.
Therefore, while absolute numbers of subsp. novicida and subsp.
holarctica recovered were similar (approx. 10
5 CFU), subsp.
holarctica was able to replicate to a much greater degree. These
differences in intramacrophage replication may not be attributed
to a defect in uptake, since Fischer 344 rat BMDM exhibited
better basal phagocytic ability to mouse BMDM. Moreover,
inclusion of homologous rat serum did not facilitate increased
uptake or replication of LVS or subsp. tularensis in rat BMDM, in
contrast to reports with human macrophages. One of the primary
differences between human and rat macrophage is the capacity to
produce NO in vitro [36,37]. Whereas human macrophages
produce minimal NO upon LPS stimulation, rat macrophages
have been shown to express 5-fold greater production of NO than
mouse cells [38]. To this end, we found that subsp. novicida and
subsp. tularensis induced the production of NO, and that addition
of a NO inhibitor during the culture period increased the overall
replication of both strains by 3 log10 at 72 h. This suggests that
Fischer 344 rat macrophages are capable of containing the
replication of these subsp. at least in part by the induction of NO.
Thus, suppression of NO production resulted in a bacterial
replication profile which more closely resembled that of hMDMs.
The in vitro intracellular replication profile of the Francisella strains
tested corresponded to in vivo susceptibility of Fischer 344 rats to
pulmonary challenge. Importantly, Fischer 344 rats were markedly
resistant to both LVS and subsp. novicida, while mice are highly
sensitive to these two avirulent human strains [11,13]. While both
subsp. tularensis and holarctica causes serious disease in humans, the
former is associated with much higher risk of mortality, which also
is reflected in the rat model by the lower pulmonary LD50 dose of
subsp. tularensis. Although there was minimal replication of subsp.
tularensis within BMDM, there was clear evidence for robust
bacterial replication in primary hepatocytes from the liver, a
known site for disseminated bacterial replication [10,24]. Howev-
er, this does not rule out the ability of subsp. tularensis to replicate
in primary macrophages isolated from the lung (alveolar
macrophages) or peritoneal cavity (ongoing studies).
The establishment of the rat model of pulmonary tularemia is
especially attractive for the screening of defined vaccine candidates,
given the similar sensitivity of the rat to the various F. tularensis
strains as humans. Mice have proven to be difficult to protect
against subsp. tularensis pulmonary challenges, and this may be due
to the extreme sensitivity of the mouse to all F. tularensis strains, even
those that cause little to no disease in humans, such as subsp. novicida
[9,10,11,13]. Because mouse infections with attenuated subsp.
novicida strains provide little to no protection against subsequent
subsp.tularensis challenge, this subspecies has beenignored largely as
a potential tularemia vaccine platform. However, in this study we
have shown that subsp. novicida vaccinated rats exhibited a polarized
Th1-type immune response and maintained a high degree of
protection to a lethal pulmonary challenge with subsp. tularensis.
These findings suggest that subsp. novicida should be reconsidered as
a potential tularemia vaccine platform. In this regard, subsp. novicida
has several distinct advantages, including the inherent low virulence
this subspecies exhibits in humans, the ease of genetic manipulation
[12,39,40], and the lack of select agent restrictions placed on this
BSL-2 organism. Thus, the rat model may be a suitable system for
the comprehensive screening of defined subsp. novicida vaccine
strains for protective efficacy against subsp. tularensis pulmonary
challenge. Our results extend those of Wu et. al. [24] who showed
that LVS vaccination of the rat provides a large window (at least 4
log10) of protection against subsp. tularensis challenge. These studies
provide evidence that the Fischer 344 rat may be an important
animal model in the development of a licensed vaccine against
human tularemia.
Materials and Methods
Ethics Statement
All animal experiments were performed in compliance with the
Animal Welfare Act, the U.S. Public Health Service Policy on
Humane Care and Use of Laboratory Animals and ‘‘Guide for the
Care and Use of Laboratory Animals’’ published by the National
Research Council. Animal work was done in accordance with the
guidelines set forth by the University of Texas at San Antonio
Institutional Animal Care and Use Committee (IACUC) under
approved protocol number MU031-11/11A0.
Animals
Four to six week old Fisher 344 rats and 4 week old BALB/c mice
were purchased from the National Cancer Institute (Bethesda,
Maryland). Animals were housed at the University of Texas at San
Antonio animal facility and given food and water ad libitum.
Figure 6. Protective efficacy of subsp. novicida vaccination
against subsequent subsp. tularensis challenge in Fischer 344
rats. Groups of Fischer 344 rats (n=6) were vaccinated intratracheally
with 10
2 or 10
5 CFU of subsp. novicida in PBS or mock vaccinated with
PBS alone. (A) Thirty days later, rats were challenged intratracheally with
subsp. tularensis (10
4 CFU) and monitored daily for morbidity and
mortality. *P=0.182, **P,0.05 (B) Fourteen days after vaccination with
10
5 CFU of subsp. novicida or PBS alone, rats were sacrificed, cervical
lymph nodes removed, and whole cell populations were recalled with
10
5 CFU of UV-inactivated subsp. novicida, media alone, or the
unrelated antigen HEL for 72 hr. Culture supernatants were analyzed
for antigen-specific IFN-c production. *P,0.001 (C) Thirty days after
vaccination with 10
5 CFU of subsp. novicida or PBS alone, blood was
collected and sera were prepared. Sera were analyzed for antigen-
specific total antibody (Ig H & L), IgG1, and IgG2a, as well as reaction to
the unrelated antigen HEL by ELISA. Results are represented as 50%
binding titers. Results are representative of two separate experiments.
*P,0.01, **P=0.118.
doi:10.1371/journal.pone.0009952.g006
Francisella in the F344 Rat
PLoS ONE | www.plosone.org 6 April 2010 | Volume 5 | Issue 4 | e9952Bacteria
Francisella tularensis (F.t.) subsp. novicida strain U112 was provided
by Dr. Francis Nano at The University of Victoria, Canada. F.t.
subsp. holarctica LVS (Lot 703-0303-016) was obtained from Dr.
Rick Lyons at The University of New Mexico. F.t. subsp. holarctica
strain OR96-0246 and F.t. subsp. tularensis strain SCHU S4 were
obtained from the Centers for Disease Control. All strains were
grown from original stocks in tryptic soy broth (TSB) or on tryptic
soy agar (TSA), each supplemented with 0.1% (w/v) L-cysteine.
Bacterial titers were determined by plating of serial dilutions on
TSA + cysteine.
Intratracheal challenges
Pulmonary challenges were performed by intratracheal inocu-
lation as described previously [24,41]. Briefly, rats were anesthe-
tized in 5% isoflurane with oxygen at 2 liters per min using a
rodent anesthesia machine (Harvard Apparatus, Holliston, MA)
and then placed dorsally on a surgical platform (Alpha Lab
Supply; Albuquerque, NM). Using a laryngeoscope blade (Penn-
Century, Inc; Philadelphia, PA) to expose the trachea and secure
the tongue, a 20 gauge plastic catheter was inserted into the
trachea. A blunt-end needle was then inserted into the plastic
sheath and 100 ml of inoculum was delivered, followed by 300 ml
of air to ensure the entire inoculum reached the lungs. The
catheter was then removed and the rats were allowed to awaken
before being returned to their cages, followed by daily monitoring
for morbidity and mortality.
Generation of bone marrow derived macrophages
Four to five week old rats and mice were euthanized by CO2
asphyxiation. Femurs were removed aseptically and washed in
Dulbecco’s Modified Eagles Medium (DMEM; Mediatech, Fair-
fax, VA) with 10% (v/v) fetal bovine serum (FBS; HyClone,
Logan, UT) supplemented with L-glutamine (2 mM) and
penicillin (100 U/ml)/streptomycin (100 mg/ml) (D10). The ends
of femurs were removed and marrow was flushed from the bones
with 10 ml of D10 and then centrifuged at 1200 RPM for 5 min at
4uC. The supernatant was discarded and the marrow was washed
two more times in D10, resuspended in conditioned media
(DMEM with 20% (v/v) FBS, L-glutamine, penicillin/streptomy-
cin and 10% (v/v) supernatant from the L929 hybridoma cell line
[42]), placed in a 75 cm
2 tissue culture flasks and incubated at
37uC with 5% CO2. After 24 hr, non-adherent cells were removed
and placed in a second flask to recover additional cells. Media was
replaced every two days while cells differentiated, with the last two
medium changes using conditioned medium without penicillin/
streptomycin, and the resulting cells were utilized 8 days after
collection. Cells were stained with mouse anti-rat CD11b
AlexaFluor 647 (AbD Serotec, Raleigh, NC) or rat anti-mouse
CD11b allophycocyanin (APC) (BD Biosciences) and determined
to be .92% pure macrophages by flow cytometry.
Fluorescent bead assay
Rat and mouse bone marrow derived macrophages (BMDM)
were suspended in DMEM, seeded in 6 well plates at a density of
1610
6 cells per well and allowed to adhere. Yellow-green
fluorescent (505/515 wavelength) carboxylate-modified micro-
spheres, (Invitrogen, Carlsbad, CA) 1.0 mm in diameter, were
added to the cells at a density of either 10 or 100 beads per cell and
incubated for 2 hr to allow for phagocytosis of the beads.
Remaining extracellular beads were then washed off, and cells
were collected into tubes, stained with either mouse anti-rat CDllb
AF647 or rat anti-mouse CD11b APC, and analyzed by flow
cytometry.
Phagocytosis assays
BMDM from Fisher 344 rats were suspended in D10, seeded
into 96-well plates at a density of 2610
5 per well, and allowed to
adhere. Macrophages were infected (10 and 100 multiplicity of
infection [MOI]) with Francisella strains for 2 hr, washed two times
with D10, gentamycin treated (20 mg/ml) for 1 hr, washed three
times with D10, and then incubated in D10 for up to 72 hr. At
indicated time points (3, 24, 48, 72 h) after challenge, supernatants
were removed and stored at 280uC for cytokine analysis. Cells
were then lysed with 0.2% deoxycholate and serial dilutions of the
lysates were plated on TSA + cysteine to determine intracellular
bacterial counts. In separate experiments, cells were lysed
immediately following the 2 hr infection period and serial dilutions
of both cell lysates and supernatants were plated to determine
bacterial numbers. In other experiments, at the time of challenge,
naı ¨ve rat serum was added as an opsonin, or 1 mM N-methyl-L-
arginine acetate salt (Sigma Aldrich, St Louis, MO) as a nitric
oxide inhibitor [43].
Analysis of culture supernatants
NO production in overnight cultures was measured as nitrite
concentration in culture supernatants by the Greiss assay
essentially as described [44]. Supernatants from in vitro phagocy-
tosis assays were analyzed by ELISA for the presence of TNFa
according to manufacturer’s instructions (BD Biosciences).
Hepatoctye isolation and intracellular replication assays
Fischer 344 rats were euthanized, livers harvested, and
hepatocytes isolated by a modification of the method of Seglen
et. al. [45]. Briefly, the liver was perfused with 100 ml of Hank’s
balanced salt solution (w/o calcium and magnesium) (HBSS;
Mediatech), followed by 100 ml of HBSS plus 5 mM calcium and
0.5 mg/ml Type IV collagenase (Sigma Aldrich) and subsequent
removal of the liver into a sterile Petri dish. The tissue was gently
disrupted to release hepatocytes and the cells were centrifuged at
29 X G for 3 min at 4uC and washed two times in HBSS.
Hepatocytes were seeded in D10 at a density of 2610
5 per well in
96 well tissue culture plates and incubated for 2 hr at 37uCt o
allow the cells to adhere. The rat hepatocytes were then infected at
an MOI of 10 or 100 with subsp. holarctica or tularensis and assayed
for intracellular bacterial replication.
Validation of vaccination efficacy of subsp. novicida
Rats were challenged intratracheally with either 10
2 or
10
5 CFU of subsp. novicida in PBS or mock-challenged with PBS
alone and rested for 30 days. Rats were then given a secondary
intratracheal challenge of 10
4 CFU of subsp. tularensis, a dose
which was previously determined [24] to be lethal to naı ¨ve rats,
and monitored daily for morbidity and mortality. To determine
cellular responses to subsp. novicida challenge, some rats were
euthanized 14 days after challenge with 10
5 CFU of the organism,
and cervical lymph nodes collected. Single cell suspensions were
prepared and cultured (1610
6 cells/well) for 72 hr in DMEM
supplemented with 10% (v/v) FBS610
5 CFU of UV-inactivated
subsp. novicida. Bacteria were inactivated by exposure to a 30 W
short wavelength UV light source for 15 min at a distance of
15 cm, and the inactivation confirmed by absence of bacterial
growth on TSA+cysteine plates. Some cells also were cultured with
the unrelated antigen hen egg lysozyme (HEL). Culture superna-
tants were harvested for IFN-c analysis by ELISA per manufac-
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humoral responses to subsp. novicida challenge, rats were bled and
sera prepared 30 days after intratracheal challenge with 10
5 CFU.
Briefly, microtiter plates were coated overnight with 10
6 CFU of
UV-inactivated subsp. novicida in sodium bicarbonate buffer
(pH 9.5), washed with PBS containing 0.3% Brij-35 (Sigma),
and blocked for 2 hr at room temperature with PBS containing
5% FBS and 0.1% Brij-35 as described previously [11]. Serial
dilutions of serum were added to wells and incubated at room
temperature for 2 hr. The plates were then washed and incubated
for an additional 2 hr with goat anti-rat total Ig, IgG1 and IgG2a
conjugated to horseradish peroxidase (Southern Biotechnology
Associates, Birmingham, AL). After incubation, the plates were
washed and teramethylbenzidine substrate (BD Biosciences, San
Diego, CA) was added for color development. The reciprocal
serum dilutions corresponding to 50% maximal binding were used
to obtain titers. No binding of immune serum was detected in
plates coated with the unrelated antigen HEL.
Statistics
SigmaStat (Systat Software Inc., San Jose, CA) was used to
perform tests of significance. Student’s t test was used to determine
differences in intracellular replication, cytokine and antibody
production. Statistical analysis for survival experiments was
performed using the Kaplan-Meier test. All data are reported as
mean 6 standard error from each experimental animal group and
are representative of at least two independent experiments.
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